People who have diabetes or have used a diabetes drug in the previous 120 days have an additional requirement: they must try and fail treatment on one of the preferred diabetes treatment versions of the weight loss drugs, or another preferred diabetes drug in the same drug class (GLP-1 receptor agonists)
They are GLP-1 patches and are science-backed. Its a bold claim, but as with many things online, it doesnt stand up to scrutiny
Clean Eatz does not prescribe, recommend, or endorse any specific peptide compounds or therapies
Your provider at Valhalla Vitality will want to discuss the risks associated with this form of treatment, such as nausea, pancreatitis, and decreased appetite, as well as any other existing medical conditions you may have that could affect the outcome of this form of treatment
Because they do not compete for the same molecular target, the post treats the combination as potentially complementary rather than conflicting, but still a provider decision
As of June 2023, Eli Lilly and Companythe pharmaceutical company behind Mounjarohas published Phase 2 clinical trial results for retatrutide in The New England Journal of Medicine
